SMT201500169B - Metodi per produrre un composto profarmaco inibitore dell'attacco di hiv e intermedi - Google Patents

Metodi per produrre un composto profarmaco inibitore dell'attacco di hiv e intermedi

Info

Publication number
SMT201500169B
SMT201500169B SM201500169T SM201500169T SMT201500169B SM T201500169 B SMT201500169 B SM T201500169B SM 201500169 T SM201500169 T SM 201500169T SM 201500169 T SM201500169 T SM 201500169T SM T201500169 B SMT201500169 B SM T201500169B
Authority
SM
San Marino
Prior art keywords
hiv
intermediates
attack
producing
methods
Prior art date
Application number
SM201500169T
Other languages
English (en)
Inventor
Jonathan Clive Tripp
Dayne Dustan Fanfair
Mitchell J Schultz
Saravanababu Murugesan
Richard J Fox
Chung-Pin H Chen
Sabrina E Ivy
Joseph Francis Payack
Wendel W Doubleday
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SMT201500169B publication Critical patent/SMT201500169B/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SM201500169T 2011-01-31 2015-07-14 Metodi per produrre un composto profarmaco inibitore dell'attacco di hiv e intermedi SMT201500169B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161437821P 2011-01-31 2011-01-31
PCT/US2012/022851 WO2012106189A1 (en) 2011-01-31 2012-01-27 Methods of making hiv attachment inhibitor prodrug compound and intermediates

Publications (1)

Publication Number Publication Date
SMT201500169B true SMT201500169B (it) 2015-09-07

Family

ID=45688987

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500169T SMT201500169B (it) 2011-01-31 2015-07-14 Metodi per produrre un composto profarmaco inibitore dell'attacco di hiv e intermedi

Country Status (25)

Country Link
US (1) US8436168B2 (it)
EP (1) EP2670751B1 (it)
JP (1) JP6006236B2 (it)
KR (1) KR101848533B1 (it)
CN (1) CN103339130B (it)
AR (1) AR085052A1 (it)
AU (1) AU2012212508B2 (it)
BR (1) BR112013018159A2 (it)
CA (1) CA2826260C (it)
CY (1) CY1116505T1 (it)
DK (1) DK2670751T3 (it)
EA (1) EA021726B1 (it)
ES (1) ES2539908T3 (it)
HR (1) HRP20150616T1 (it)
HU (1) HUE026880T2 (it)
IL (1) IL227302A (it)
MX (1) MX2013008371A (it)
PL (1) PL2670751T3 (it)
PT (1) PT2670751E (it)
RS (1) RS54055B1 (it)
SG (1) SG191841A1 (it)
SI (1) SI2670751T1 (it)
SM (1) SMT201500169B (it)
TW (1) TW201309692A (it)
WO (1) WO2012106189A1 (it)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
WO2010085456A1 (en) 2009-01-20 2010-07-29 Guided Delivery Systems Inc. Anchor deployment devices and related methods
MX352320B (es) * 2012-02-08 2017-11-21 Viiv Healthcare Uk No 4 Ltd Metodos para la preparacion del compuesto profarmaco de piperazina inhibidor de la union de virus de inmunodeficiencia humana.
JP6693891B2 (ja) 2014-06-23 2020-05-13 フリー フォーム ファイバーズ リミテッド ライアビリティ カンパニー 核燃料構造体及び核燃料構造体を作製する方法
BR112017012643A2 (pt) 2014-12-18 2018-01-09 Viiv Healthcare Uk No 4 Ltd processo para preparação de um composto, e, método para fabricação de um composto.
BR112017012716A2 (pt) 2014-12-18 2018-03-13 Viiv Healthcare Uk No 4 Ltd processo para preparação de um composto, e, método para fabricação de um composto.
EP4292551A3 (en) * 2015-03-05 2024-01-31 Ancora Heart, Inc. Devices of visualizing and determining depth of penetration in cardiac tissue
JP7429236B2 (ja) 2019-01-17 2024-02-07 ヴィーブ ヘルスケア ユーケー(ナンバー4)リミテッド ホステムサビルの調製方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US7776863B2 (en) 2004-03-24 2010-08-17 Bristol-Myers Squibb Company Methods of treating HIV infection
US7601715B2 (en) * 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine

Also Published As

Publication number Publication date
CN103339130A (zh) 2013-10-02
WO2012106189A1 (en) 2012-08-09
EA021726B1 (ru) 2015-08-31
US20130030178A1 (en) 2013-01-31
PT2670751E (pt) 2015-07-29
RS54055B1 (en) 2015-10-30
CA2826260A1 (en) 2012-08-09
EA201391123A1 (ru) 2013-12-30
CN103339130B (zh) 2015-05-06
JP6006236B2 (ja) 2016-10-12
CA2826260C (en) 2018-09-04
IL227302A (en) 2016-10-31
AU2012212508A1 (en) 2013-09-19
JP2014503594A (ja) 2014-02-13
MX2013008371A (es) 2013-08-12
US8436168B2 (en) 2013-05-07
SG191841A1 (en) 2013-08-30
HRP20150616T1 (hr) 2015-07-03
PL2670751T3 (pl) 2015-09-30
CY1116505T1 (el) 2017-03-15
AR085052A1 (es) 2013-08-07
IL227302A0 (en) 2013-09-30
DK2670751T3 (en) 2015-07-20
EP2670751B1 (en) 2015-04-22
BR112013018159A2 (pt) 2018-09-11
HUE026880T2 (en) 2016-08-29
AU2012212508B2 (en) 2016-01-14
ES2539908T3 (es) 2015-07-07
KR20140014154A (ko) 2014-02-05
TW201309692A (zh) 2013-03-01
SI2670751T1 (sl) 2015-07-31
EP2670751A1 (en) 2013-12-11
KR101848533B1 (ko) 2018-04-12

Similar Documents

Publication Publication Date Title
SMT201500169B (it) Metodi per produrre un composto profarmaco inibitore dell'attacco di hiv e intermedi
SMT201600060B (it) Procedimenti e intermedi per la produzione di un inibitore di jak
NL301191I2 (nl) voxelotor of een tautomeer of farmaceutisch aanvaardbaar zout daarvan
NL301119I2 (nl) Selinexor of een farmaceutisch aanvaardbaar zout ervan
NO2021040I1 (no) glecaprevir or a pharmaceutically acceptable salt or ester thereof- forlenget SPC
SMT201600206B (it) Processo per la produzione di intermedi dell'estetrolo
SMT201600375B (it) Procedimento per la produzione di estetrolo
BR112014010750A2 (pt) produção de isoprenoides derivados de acetil-coenzima a
BR112014015481A8 (pt) método de feitura de um metal duro
ITAN20120150A1 (it) Servomeccanismo per l'apertura di una serratura.
BR112013013028A2 (pt) processo para a preparação de derivados de carbamato de fenila
BR112013019525A2 (pt) método para a produção de 2,3-butanodiol por fermentação
BR112013019524A2 (pt) método para a produção de 2,3-butanodiol por fermentação
ITMI20112060A1 (it) Procedimento per la produzione di un componente micromeccanico
FI20145302L (fi) Menetelmä metallin erottamiseksi katodista
RS55354B1 (sr) Postupak za prognozu napredovanja hiv-a
BR112013029649A2 (pt) "processo para a preparação de aminopolicarboxilatos"
FR2974589B1 (fr) Element de coffrage pour la fabrication d'un linteau
ITMI20110184A1 (it) Composti fotosensibilizzanti "metal free"
IL230114A (en) Process for the production of compound 2 - (arylaxymethyl) benzaldehyde
FR2984080B1 (fr) Methode pour la fabrication d'une composition parasiticide
PL2689039T3 (pl) Sposób krystalizacji związku rozpuszczalnego w wodzie
FR2972655B1 (fr) Procede d'obtention d'une piece metallique a partir d'un modele perdu
IT1398542B1 (it) Processo per la preparazione di un polimorfo
NL301097I2 (nl) acalabrutinib of een farmaceutisch aanvaardbaar zout daarvan